OmniAb (OABI) Equity Average (2021 - 2026)
OmniAb (OABI) reported Equity Average of $264.8 million for Q1 2026, down 5.61% year-over-year from $280.6 million in Q1 2025, and down 2.72% on a QoQ basis from $272.2 million in Q4 2025.
OmniAb (OABI) has 6 years of Equity Average data on file, last reported at $264.8 million in Q1 2026.
- Quarterly Equity Average fell 5.61% year-over-year to $264.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $264.8 million (down 5.61% YoY) and the FY2025 annual result came in at $277.3 million, down 7.9% from the prior year.
- Equity Average eased to $264.8 million in Q1 2026 per OABI's latest filing, from $272.2 million in the prior quarter.
- Across five years, Equity Average topped out at $341.1 million in Q1 2023 and bottomed at $225.9 million in Q2 2022.
- The 5-year median for Equity Average is $287.0 million (2022), against an average of $284.9 million.
- The widest annual swing landed in 2022, when Equity Average soared 1401332.87%; it then declined 11.72% in 2024.
- Tracing OABI's Equity Average over 5 years: stood at $287.0 million in 2022, then gained by 11.33% to $319.6 million in 2023, then retreated by 9.35% to $289.7 million in 2024, then declined by 6.02% to $272.2 million in 2025, then decreased by 2.72% to $264.8 million in 2026.
- Per Business Quant, the three latest OABI Equity Average figures stand at $264.8 million (Q1 2026), $272.2 million (Q4 2025), and $269.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 264.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264.84 Mn |
| Dec 31, 2025 | 272.24 Mn |
| Sep 30, 2025 | 269.75 Mn |
| Jun 30, 2025 | 267.79 Mn |
| Mar 31, 2025 | 280.57 Mn |
| Dec 31, 2024 | 289.67 Mn |
| Sep 30, 2024 | 292.95 Mn |
| Jun 30, 2024 | 297.79 Mn |
| Mar 31, 2024 | 307.99 Mn |
| Dec 31, 2023 | 319.57 Mn |
| Sep 30, 2023 | 329.18 Mn |
| Jun 30, 2023 | 337.30 Mn |
| Mar 31, 2023 | 341.09 Mn |
| Dec 31, 2022 | 287.04 Mn |
| Sep 30, 2022 | 229.83 Mn |
| Jun 30, 2022 | 225.93 Mn |
| Mar 31, 2022 | 229.61 Mn |
| Dec 31, 2021 | 113.70 Mn |
| Sep 30, 2021 | -3.44 Mn |
| Jun 30, 2021 | 16,121.50 |